LIDDS publishes supplementary prospectus
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER REGARDING ANY SECURITIES IN LIDDS AB. SEE ALSO THE “IMPORTANT INFORMATION” SECTION BELOW.
The Board of Directors of LIDDS AB (publ) (”LIDDS” or the ”Company”) has prepared a supplement (the ”Supplementary Prospectus”) to the EU-Growth prospectus that was published on January 17, 2023 (the ”Prospectus”). The Supplementary Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen).
The Supplementary Prospectus has been prepared because LIDDS noticed an error on page 43 of the Prospectus regarding the table of subscription commitments and guarantee commitments. It states that Galba Holding AB has entered into a guarantee commitment amounting to SEK 1,050,000. Correct is that the amount refers to a subscription commitment. The table is adjusted so that SEK 1,050,000 is added under Subscription commitment at Galba Holding AB and the amount SEK 1,050,000 is removed from Guarantee commitment. The Supplementary Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority and is available on the Company's website (www.liddspharma.com) and on Erik Penser Bank's website (www.penser.se). The supplementary prospectus will also be available on the Financial Supervisory Authority's website (www.fi.se).
Investors who, prior to the publication of this Supplemental Prospectus, have made a notification about or otherwise consented to the purchase or subscription of the securities covered by the Prospectus have, according to Article 23 of the Prospectus Ordinance, the right to withdraw their notification or consent within two days of the publication of the Supplemental Prospectus, that is, until January 24, 2023.
Revocation must be notified to Erik Penser Bank AB, subject: LIDDS, e-mail: [email protected]. The date of revocation taken into account is the date on which the e-mail was received by Erik Penser Bank. Investors who have subscribed for shares through nominees must contact their nominees regarding revocation. Subscriptions that are not revoked will remain binding.
InDex Pharmaceuticals updates the timeline of the phase III study CONCLUDE with cobitolimod
January 27, 2023 – InDex Pharmaceuticals Holding AB (publ) today announced an update in the timing of the dose selection in the ongoing phase III study CONCLUDE with the drug candidate cobitolimod. The outcome of the dose selection is expected to be available Q4 2023. At that point in time InDex wil...
InDex Pharmaceuticals uppdaterar tidplanen för fas III-studien CONCLUDE med cobitolimod
27 januari, 2023 – InDex Pharmaceuticals Holding AB (publ) meddelar idag en uppdatering av tidplanen för valet av dos i den pågående fas III-studien CONCLUDE med läkemedelskandidaten cobitolimod. Utfallet av dosvalet förväntas fjärde kvartalet 2023. Vid den tidpunkten har InDex slutfört bedömning av...
Mentice’s CEO Göran Malmberg to present the company’s Year-end Report Q4 2022 at a earnings call on February 3rd at 10:00 CET
The presentation of the Year-end Report Q4 for the period October – December 2022 will be held on February 3rd, 2023, at 10:00 CET. The live broadcast is followed by a Q&A moderated by Redeye’s analyst Christian Binder. For more information on how to register, please visit https://investor.menti...